Shore Capital Reiterates “House Stock” Rating for Poolbeg Pharma (LON:POLB)

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reissued by Shore Capital in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Poolbeg Pharma Trading Up 1.5%

Poolbeg Pharma stock opened at GBX 4.47 on Wednesday. The company has a fifty day simple moving average of GBX 4.11 and a 200 day simple moving average of GBX 3.69. Poolbeg Pharma has a 1-year low of GBX 2.25 and a 1-year high of GBX 5.40. The company has a market cap of £31.15 million, a P/E ratio of -3.92 and a beta of 2.11.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.